Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Lorenzo-Lupo Dei"'
Autor:
Antonio Scarà, Zefferino Palamà, Antonio Gianluca Robles, Lorenzo-Lupo Dei, Alessio Borrelli, Federico Zanin, Leonardo Pignalosa, Silvio Romano, Luigi Sciarra
Publikováno v:
Journal of Cardiovascular Development and Disease, Vol 11, Iss 4, p 122 (2024)
Heart failure (HF) represents a significant global health challenge that is still responsible for increasing morbidity and mortality despite advancements in pharmacological treatments. This review investigates the effectiveness of non-pharmacological
Externí odkaz:
https://doaj.org/article/e5eeab5fa2b34ad1b3ff78fd6a1812d1
Publikováno v:
Life, Vol 12, Iss 8, p 1191 (2022)
In recent years, new interest is growing in the left atrium (LA). LA functional analysis and measurement have an essential role in cardiac function evaluation. Left atrial size and function are key elements during the noninvasive analysis of diastoli
Externí odkaz:
https://doaj.org/article/a1c3b8e47c854233801c8957b1d55736
Autor:
Alessia Argirò, Mattia Zampieri, Lorenzo-Lupo Dei, Cecilia Ferrantini, Alberto Marchi, Alessia Tomberli, Katia Baldini, Francesco Cappelli, Silvia Favilli, Silvia Passantino, Chiara Zocchi, Luigi Tassetti, Martina Gabriele, Niccolò Maurizi, Niccolò Marchionni, Raffaele Coppini, Iacopo Olivotto
Publikováno v:
International Journal of Cardiology. 370:271-278
We assessed the efficacy and safety of ranolazine in real-world patients with hypertrophic cardiomyopathy (HCM).Ranolazine is an anti-anginal drug that inhibits the late phase of the inward sodium current. In a small prospective trial, ranolazine red
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1fb48d655e474bfebd61fb970ddffb9
https://doi.org/10.1016/j.ijcard.2022.10.014
https://doi.org/10.1016/j.ijcard.2022.10.014
Autor:
Elena Silvestri, Matteo Beltrami, Domenico Prisco, Mattia Zampieri, Carlo Fumagalli, Silvia Pradella, Maria Letizia Urban, Lorenzo-Lupo Dei, Augusto Vaglio, Alessandra Bettiol, Alberto Marchi, Katia Baldini, Giacomo Emmi, Martina Berteotti, Iacopo Olivotto, Niccolò Marchionni, Alessia Tomberli
Publikováno v:
European Journal of Internal Medicine. 85:68-79
Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare systemic vasculitis. Cardiac specific involvement (CSI) is caused by coronary artery vasculitis, but also by myocardial eosinophilic infiltration. To date, the prevalence of CS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28b24d13e765f3207a807887c472192f
https://doi.org/10.1016/j.ejim.2020.12.008
https://doi.org/10.1016/j.ejim.2020.12.008
Publikováno v:
Journal of Clinical Medicine. 11:2243
Patients with heart failure (HF) and associated chronic kidney disease (CKD) are a population less represented in clinical trials; additionally, subjects with more severe estimated glomerular filtration rate reduction are often excluded from large st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17bbe0a2410379a4d10393658f649dc2
https://doi.org/10.3390/jcm11082243
https://doi.org/10.3390/jcm11082243
Autor:
Gaetano Todde, Lorenzo Lupo Dei, Roberto Polizzi, Domenico Gabrielli, Grazia Canciello, Silvio Romano, Felice Borrelli, Geza Halasz, Leopoldo Ordine, Salvatore Di Napoli, Daniela Pacella, Raffaella Lombardi, Giovanni Esposito, Federica Re, Maria-Angela Losi
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
BackgroundIn obstructive hypertrophic cardiomyopathy (HOCM), disopyramide is used in patients who remain symptomatic despite β-blockers or verapamil. However, effectiveness of disopyramide therapy has not been clearly established due to inconsistent
Externí odkaz:
https://doaj.org/article/d69e4b7fe26d4aa7aa040b1585ee1fa9